重复测量FIB-4有助于识别严重肝病风险个体
基于瑞典AMORIS人群队列,在5年内重复计算FIB-4并与严重肝病结局关联。FIB-4每增加1单位与严重肝病风险升高相关(aHR 1.81;95%CI 1.67-1.96),持续高危者风险最高(aHR 17.04;95%CI 11.67-24.88),但近半数事件发生在持续低危组。结论认为重复检测可改善风险识别,但敏感性较低,需改进检测用于筛查。
要点
- FIB-4每升高1单位,严重肝病风险升高(aHR 1.81;95%CI 1.67-1.96)。
- 由低危或中危转为高危者较持续低危者风险升高(aHR 7.99和8.64)。
- 持续高危者风险最高(aHR 17.04;95%CI 11.67-24.88),但近半数事件在持续低危组。
核心结论
- 5年内重复检测FIB-4可改善对一般人群严重肝病风险个体的识别。
- 但敏感性相对较低,需改进检测用于一般人群或初级保健筛查。
研究设计与样本
- 数据来自基于人群的瑞典AMORIS队列,基线检查时间为1985-1996年。
- 在5年内两个时间点计算FIB-4,并与结局关联。
- 126,942名有FIB-4数据的个体中,40,729名(32.1%)在5年内进行了第二次检测(平均间隔2.4年)。
- 通过链接瑞典国家登记处获取至2011年的新发严重肝病数据,采用Cox回归计算风险比(HR)和置信区间(CI)。
主要发现
- 随访613,376人年期间,记录到581例严重肝病事件(0.95/1,000人年)。
- FIB-4每增加1单位与严重肝病风险升高相关(校正风险比[aHR] 1.81;95%CI 1.67-1.96)。
- 由低危转为高危者较持续低危者严重肝病风险升高(aHR 7.99)。
- 由中危转为高危者较持续低危者严重肝病风险升高(aHR 8.64)。
- 两次检测均定义为高危者严重肝病风险尤其升高(aHR 17.04;95%CI 11.67-24.88)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出FIB-4敏感性相对较低。
- 原文指出需要改进检测用于一般人群或初级保健筛查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: It is unclear whether the identification of individuals at risk of cirrhosis using non-invasive tests can be improved by repeated measurements. Herein, we tested whether repeated measurements of fibrosis-4 index (FIB-4) could improve the identification of individuals at risk of severe liver disease. METHODS: Data were derived from the population-based Swedish AMORIS cohort with baseline examinations from 1985-1996. FIB-4 was calculated at 2 time points within 5 years. Thereafter, we associated changes in FIB-4 with outcomes. Incident severe liver disease data was ascertained through linkage to Swedish national registers until 2011. Hazard ratios (HRs) and CIs for outcomes were calculated using Cox regression. RESULTS: Of 126,942 individuals with available FIB-4 data, 40,729 (32.1%) underwent a second test within 5 years (mean interval 2.4 years). During 613,376 person-years of follow-up, 581 severe liver disease events were documented (0.95/1,000 person-years). An increase of 1 unit in FIB-4 was associated with an elevated risk of severe liver disease (adjusted hazard ratio [aHR] 1.81; 95% CI 1.67-1.96). Transitioning from a low- or intermediate- to a high-risk group was associated with an increased risk of severe liver disease compared with those consistently in the low-risk group (aHR 7.99 and 8.64, respectively). A particularly increased risk of severe liver disease was found in individuals defined as high risk at both tests (aHR 17.04; 95% CI 11.67-24.88). However, almost half of all events occurred in those consistently in the low-risk group. CONCLUSIONS: Repeated testing of FIB-4 within 5 years improves the identification of individuals at an increased risk of severe liver disease in the general population. However, the sensitivity is comparatively low and improved tests are needed for screening in a general population or primary care setting. LAY SUMMARY: The fibrosis-4 scoring system is often used to estimate the risk of advanced fibrosis in liver diseases. Herein, we found that changes in this score over time are associated with the risk of future severe liver disease in a population-based cohort. However, even if the prediction is improved by repeated testing, the overall ability of the score to predict future events is relatively low.
引用
- Hagström H, Talbäck M, Andreasson A, et al. Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease. J Hepatol. 2020. PMID: 32621944. doi:10.1016/j.jhep.2020.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。